January 30, 2019 04:29 PM EST
R&D
Pharma

Af­ter a years-long re­prieve, GSK is about to see My­lan’s gener­ic carve in­to its mega-block­buster Ad­vair fran­chise

John Carroll

Editor & Founder

And so it ends.

Af­ter mul­ti­ple de­lays, My­lan has won FDA ap­proval for a gener­ic ver­sion of Ad­vair, Glax­o­SmithK­line’s mega-block­buster asth­ma/COPD drug. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times